Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age

Women remain at risk of human papillomavirus (HPV) infection for most of their lives. The duration of protection against HPV‐16/18 from prophylactic vaccination remains unknown. We investigated the 10‐year immune response and long‐term safety profile of the HPV‐16/18 AS04‐adjuvanted vaccine (AS04‐HP...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Tino F., Galaj, Andrzej, Spaczynski, Marek, Wysocki, Jacek, Kaufmann, Andreas M., Poncelet, Sylviane, Suryakiran, Pemmaraju V., Folschweiller, Nicolas, Thomas, Florence, Lin, Lan, Struyf, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Cancer Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673947/
https://www.ncbi.nlm.nih.gov/pubmed/28984053
http://dx.doi.org/10.1002/cam4.1155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673947/
https://www.ncbi.nlm.nih.gov/pubmed/28984053
http://dx.doi.org/10.1002/cam4.1155

Ejemplares similares